telmisartan has been researched along with Abdominal Obesity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anand, SS; Chetty, VT; Damjanovic, S; Gerstein, H; Sharma, AM; Singh, N; Yusuf, S | 1 |
| Ebihara, K; Kusakabe, T; Kuwahara, K; Li, Y; Murray, M; Nakao, K; Naowaboot, J; Rong, X; Zhao, M | 1 |
1 trial(s) available for telmisartan and Abdominal Obesity
| Article | Year |
|---|---|
Metabolic effects of telmisartan in subjects with abdominal obesity: a prospective randomized controlled trial.
Topics: Adiponectin; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Female; Humans; Insulin Resistance; Lipid Metabolism; Male; Middle Aged; Obesity, Abdominal; Prospective Studies; Single-Blind Method; Telmisartan | 2014 |
1 other study(ies) available for telmisartan and Abdominal Obesity
| Article | Year |
|---|---|
Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice.
Topics: Adipocytes; Adipose Tissue, White; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Cell Size; Diet, High-Fat; Fatty Liver; Insulin; Insulin Resistance; Leptin; Lipids; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Skeletal; Obesity, Abdominal; Organ Size; PPAR gamma; Receptor, Angiotensin, Type 1; Telmisartan; Triglycerides | 2010 |